Disease and economic burden of refractory versus non-refractory generalized myasthenia gravis in China: a cross-sectional study

Generalized myasthenia gravis (gMG) imposes multifaceted burdens on patients in China. This study assessed the disease and economic burden of gMG among adult patients and their caregivers, comparing refractory and non-refractory cases. An online cross-sectional survey (April to May 2025) recruited 300 patients through physician referral, with enriched enrollment of refractory patients. All estimates for the total sample are based directly on the surveyed sample without weighting. Burden domains included marital and childbearing impact, work impairment, quality of life (EQ-5D-5 L for patients; CarerQol-7D for caregivers), clinical unmet needs, and economic burden. Work time and efficiency loss were measured with the Work Productivity and Activity Impairment (WPAI) questionnaire. A total of 300 patients (124 male, 176 female) were included; based on the refractory criteria, 122 were classified as refractory and 178 as non-refractory. The annual per capita economic burden was $11,491. Medical service resource use accounted for the largest share of direct costs (60.2%), and 55.7% of families experienced catastrophic health expenditure. Refractory patients incurred a substantially higher overall economic burden than non-refractory patients ($13,954 vs. $9,803), and caregiver productivity loss averaged $935. gMG also affected patients’ social functioning and quality of life: 75.0% of divorced or separated patients attributed their divorce or separation to gMG, 57.0% of patients reported that gMG would affect future childbearing plans, and total work impairment among employed patients was 36.8%. The mean health utility value was 0.829, and 91.7% of patients experienced adverse reactions. Patients with gMG in China face substantial burdens in terms of social function, quality of life, and financial stability, and the burden is heavier among refractory patients. These findings highlight the need for effective treatment and social support to improve quality of life, and for targeted policies to reduce the disease and economic burden. Generalized myasthenia gravis (gMG) is a rare disease that causes muscle weakness. Little is known about how it affects patients’ daily lives, work, family, finances, and quality of life in China. This study compared the overall burden between patients whose symptoms are difficult to control (refractory) and those who respond better to treatment (non-refractory). Using standardized questionnaires, we measured how gMG affected patients’ ability to work, childbearing plans, health, finances, and their quality of life. Among the 300 patients surveyed, 75.0% of those who were divorced or separated cited gMG as the reason, 57.0% reported that gMG would affect their childbearing plans, and work impairment among employed patients was 36.8%. The average health-related quality-of-life score was 0.829, and 91.7% of patients experienced treatment side effects. The average yearly cost was about $11,491, caregivers lost $935 per year in productivity, and 55.7% of families faced catastrophic health expenditure. These findings show that gMG places a heavy physical, emotional, and economic burden on patients and their families, especially among those with refractory disease.

Authors

Institutions

Publication Details

Journal
Health Economics Review
Published
2026-11-17
DOI
https://doi.org/10.1186/s13561-026-00894-x
Primary Topic
Myasthenia Gravis and Thymoma
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Disease and economic burden of refractory versus non-refractory generalized myasthenia gravis in China: a cross-sectional study

Wenxi Tang, Liying Geng, Yuhong Liu, Yue Yin et al.
4 links
Health Economics Review
Myasthenia Gravis and Thymoma
article

Disease and economic burden of refractory versus non-refractory generalized myasthenia gravis in China: a cross-sectional study

Wenxi Tang, Liying Geng, Yuhong Liu, Yue Yin, Dachuang Zhou
article en

Abstract

Generalized myasthenia gravis (gMG) imposes multifaceted burdens on patients in China. This study assessed the disease and economic burden of gMG among adult patients and their caregivers, comparing refractory and non-refractory cases. An online cross-sectional survey (April to May 2025) recruited 300 patients through physician referral, with enriched enrollment of refractory patients. All estimates for the total sample are based directly on the surveyed sample without weighting. Burden domains included marital and childbearing impact, work impairment, quality of life (EQ-5D-5 L for patients; CarerQol-7D for caregivers), clinical unmet needs, and economic burden. Work time and efficiency loss were measured with the Work Productivity and Activity Impairment (WPAI) questionnaire. A total of 300 patients (124 male, 176 female) were included; based on the refractory criteria, 122 were classified as refractory and 178 as non-refractory. The annual per capita economic burden was $11,491. Medical service resource use accounted for the largest share of direct costs (60.2%), and 55.7% of families experienced catastrophic health expenditure. Refractory patients incurred a substantially higher overall economic burden than non-refractory patients ($13,954 vs. $9,803), and caregiver productivity loss averaged $935. gMG also affected patients’ social functioning and quality of life: 75.0% of divorced or separated patients attributed their divorce or separation to gMG, 57.0% of patients reported that gMG would affect future childbearing plans, and total work impairment among employed patients was 36.8%. The mean health utility value was 0.829, and 91.7% of patients experienced adverse reactions. Patients with gMG in China face substantial burdens in terms of social function, quality of life, and financial stability, and the burden is heavier among refractory patients. These findings highlight the need for effective treatment and social support to improve quality of life, and for targeted policies to reduce the disease and economic burden. Generalized myasthenia gravis (gMG) is a rare disease that causes muscle weakness. Little is known about how it affects patients’ daily lives, work, family, finances, and quality of life in China. This study compared the overall burden between patients whose symptoms are difficult to control (refractory) and those who respond better to treatment (non-refractory). Using standardized questionnaires, we measured how gMG affected patients’ ability to work, childbearing plans, health, finances, and their quality of life. Among the 300 patients surveyed, 75.0% of those who were divorced or separated cited gMG as the reason, 57.0% reported that gMG would affect their childbearing plans, and work impairment among employed patients was 36.8%. The average health-related quality-of-life score was 0.829, and 91.7% of patients experienced treatment side effects. The average yearly cost was about $11,491, caregivers lost $935 per year in productivity, and 55.7% of families faced catastrophic health expenditure. These findings show that gMG places a heavy physical, emotional, and economic burden on patients and their families, especially among those with refractory disease.

Health Economics Review
China Pharmaceutical University (CN)
Good health and well-being
Myasthenia Gravis and Thymoma
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon